BONE BIOLOGICS CORP (BBLG)

Company Profile

Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The company is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. The company is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Company Info

BONE BIOLOGICS CORP

2 Burlington Woods Dr Ste 100

Burlington MASSACHUSETTS

P: 17815524452

Employees: 2

Website: https://www.bonebiologics.com/